Search Results - "Naylor, Maria L."

Essential role of limiting telomeres in the pathogenesis of Werner syndrome by Chang, Sandy, DePinho, Ronald A, Multani, Asha S, Cabrera, Noelia G, Naylor, Maria L, Laud, Purnima, Lombard, David, Pathak, Sen, Guarente, Leonard

“…Mutational inactivation of the gene WRN causes Werner syndrome, an autosomal recessive disease characterized by premature aging, elevated genomic instability…”
Get full text

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate by Scott, Thomas F., Su, Ray, Xiong, Kuangnan, Altincatal, Arman, Castrillo-Viguera, Carmen, Naylor, Maria L.

“…Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but…”
Get full text

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers by Zhao, Yuan, Chen, Kun, Ramia, Nancy, Sahu, Sangeeta, Kumar, Achint, Naylor, Maria L., Zhu, Li, Naik, Himanshu, Butts, Cherié L.

“…Background: Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting…”
Get full text

RAD51-Dependent Break-Induced Replication Differs in Kinetics and Checkpoint Responses from RAD51-Mediated Gene Conversion by Malkova, Anna, Naylor, Maria L., Yamaguchi, Miyuki, Ira, Grzegorz, Haber, James E.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN by Newsome, Scott D., Scott, Thomas F., Arnold, Douglas L., Nelles, Gereon, Hung, Serena, Cui, Yue, Shang, Shulian, Naylor, Maria L., Kremenchutzky, Marcelo

“…Background: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with…”
Get full text

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis by Arnold, Douglas L., Shang, Shulian, Dong, Qunming, Meergans, Matthias, Naylor, Maria L.

“…Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease…”
Get full text

Mrc1 Phosphorylation in Response to DNA Replication Stress Is Required for Mec1 Accumulation at the Stalled Fork by Naylor, Maria L., Li, Ju-mei, Osborn, Alex J., Elledge, Stephen J.

“…DNA replication stress activates a response pathway that stabilizes stalled forks and promotes the completion of replication. The budding yeast Med sensor…”
Get full text

Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression by Chang, Sandy, Khoo, Christine M, Naylor, Maria L, Maser, Richard S, DePinho, Ronald A

“…Telomerase activation is a common feature of most advanced human cancers and is postulated to restore genomic stability to a level permissive for cell…”
Get full text

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies by Reder, Anthony T., Centonze, Diego, Naylor, Maria L., Nagpal, Anjali, Rajbhandari, Rajani, Altincatal, Arman, Kim, Michelle, Berdofe, Aaron, Radhakrishnan, Maha, Jung, Eunice, Sandrock, Alfred W., Smirnakis, Karen, Popescu, Catrinel, de Moor, Carl

“…Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute…”
Get full text

Profiling DNA damage-induced phosphorylation in budding yeast reveals diverse signaling networks by Zhou, Chunshui, Elia, Andrew E. H., Naylor, Maria L., Dephoure, Noah, Ballif, Bryan A., Goel, Gautam, Xu, Qikai, Ng, Aylwin, Chou, Danny M., Xavier, Ramnik J., Gygi, Steven P., Elledge, Stephen J.

“…The DNA damage response (DDR) is regulated by a protein kinase signaling cascade that orchestrates DNA repair and other processes. Identifying the substrate…”
Get full text

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions by Cohen, Jeffrey A, Bermel, Robert A, Grossman, Cynthia I, Hersh, Carrie M, Hyland, Megan, Mowry, Ellen M, Naismith, Robert, Naylor, Maria L, Nicholas, Jacqueline, Rajbhandar, Rajani, Singh, Carol M, Tintorè, Mar, Zabalza, Ana, Ziemssen, Tjalf, Williams, James R, Montalban, Xavier

“…Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2…”
Get full text

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program by Salvetti, Marco, Wray, Sibyl, Nelles, Gereon, Altincatal, Arman, Kumar, Achint, Koster, Thijs, Naylor, Maria L.

“…•The safety of peginterferon beta-1a in POP was consistent with clinical trials.•FLS and ISRs were significant predictors of earlier treatment…”
Get full text

Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN by Newsome, Scott D., Scott, Thomas F., Arnold, Douglas L., Altincatal, Arman, Naylor, Maria L.

“…•Early peginterferon beta-1a initiation was associated with better 2-year outcomes.•Early treatment reduced black hole conversion from new/enlarging T2 or Gd+…”
Get full text

Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide by Newsome, Scott D., Mokliatchouk, Oksana, Castrillo-Viguera, Carmen, Naylor, Maria L.

“…•A matching-adjusted comparison was made of peginterferon beta-1a and teriflunomide.•24-week CDW was significantly lower for peginterferon beta-1a vs…”
Get full text

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach by White, Sarah, Harris, Colleen, Allan, Michelle, Chieffe, Carol, Eelen, Piet, Röder, Claudia, Mouzawak, Catherine, Naylor, Maria L.

“…Introduction Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis (MS) treated with…”
Get full text

Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial by Cutter, Gary, Rudick, Richard A, de Moor, Carl, Singh, Carol M, Fisher, Elizabeth, Koster, Thijs, Lublin, Fred D, Wolinsky, Jerry S, McFarland, Henry, Jacobson, Steven, Naylor, Maria L

“…Background CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients…”
Get full text

1111 Increasing access and quality of care for individuals from underrepresented communities living with lupus: insights from qualitative interviews with patients and physicians by Sheikh, Saira Z, Naylor, Maria L, O’Callaghan, Lasair, Sladkeviciute, Lina, Gaiha-Rohrbach, Janine, Butts, Cherie

“…BackgroundLupus disproportionately affects Black/African American (AA) and Latino/a patients, yet these underrepresented racial/ethnic minority populations…”
Get full text

RAD51-independent break-induced replication to repair a broken chromosome depends on a distant enhancer site by Malkova, A, Signon, L, Schaefer, C B, Naylor, M L, Theis, J F, Newlon, C S, Haber, J E

“…Without the RAD51 strand exchange protein, Saccharomyces cerevisiae cannot repair a double-strand break (DSB) by gene conversion. However, cells can repair…”
Get full text

Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945) by Galetta, Steven L., Balcer, Laura J., Altincatal, Arman, Jiang, Xiaotong, Aktas, Orhan, Naylor, Maria L.

“…Abstract only…”
Get full text

Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis ADVANCE by Arnold, Douglas, Mokliatchouk, Oksana, Naylor, Maria L.

“…Chronic black holes (BHs) indicate severe tissue injury and are used as a biomarker of therapeutic outcomes in relapsing-remitting multiple sclerosis (RRMS)…”
Get full text